Address

MaRS Center, South Tower

101 College Street, Suite 300

Toronto, ON, M5G 1L7


Get in touch
Hovione and Ripple Enter Strategic Partnership to Expand Epidel Platform into Non-Ophthalmic Space

Lisbon, March 20, 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications.

 

The core feature of Ripple’s Epidel® technology is the ability to deliver sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. This enables higher drug loading, smaller size implants, defined and predictable biocompatible degradation products with straightforward and scalable manufacturing processes. Surface erosion-based drug release provides a highly effective way to control dose and duration. By incorporating Ripple's Epidel® platform into its toolbox, Hovione can expand its portfolio of novel drug delivery solutions to the pharmaceutical industry.

 

“The combination of technology synergy, innovative vision and cultural fit makes collaborating with Hovione an exciting next step in the advancement of the Epidel® platform beyond the ophthalmic field,” stated Dr. Wendy Naimark, Ripple co-founder and Chief Technology Officer. “Hovione’s expertise in controlled, sustained drug delivery, along with their experience in chemical synthesis and pharmaceutical manufacturing, makes for a great partnership.”

 

"We are thrilled to partner with Ripple, who developed a state-of-the-art platform for sustained release," says Dr. Jean-Luc Herbeaux, Hovione's CEO. " Our shared goal is to accelerate and broaden the access to this highly innovative and enabling technology for the benefit of our pharmaceutical customers and their patients worldwide."


By extending the use of the Epidel® platform beyond ocular applications, this partnership will enable the development of a diverse range of new products with optimal sustained release profiles.

 

About Hovione:

Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione's culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

 

About Ripple Therapeutics:

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. Ripple’s novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors. Ripple has a full product pipeline in development. www.rippletherapeutics.com

 

For more information, please visit www.hovione.com or contact:

Vanessa Romeu | Communications Director | vromeu@hovione.com |Tel: +351 21 982 9000

Or visit www.rippletherapeutics.com or contact:

Julie Fotheringham | V.P. Marketing, People & Culture | 416-951-7988| jfotheringham@rippletherapeutics.com

October 15, 2024
TORONTO, CANADA / ACCESSWIRE / October 15, 2024 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce evaluation and licensing agreements with Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal disease. Ripple’s patented technology platform is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor both drug dose and duration. The advantages of this technology include lower molecular weight and higher drug loading allowing for smaller implants and a lack of degradation products which provides both a clearer regulatory path as well as an improved safety profile. With an extended duration of therapeutic benefit, this technology will also reduce the treatment burden for patients. These agreements enable Glaukos to leverage Ripple’s proprietary technology platform to create sustained release implants of targeted APIs for both glaucoma and retinal diseases. If the program is successful, the evaluation agreement will automatically convert into a licensing agreement with future milestone payments and royalties. “We believe Ripple has one of the most promising drug delivery technologies currently under development,” commented Tomas Navratil, PhD, Chief Development Officer, Glaukos. “We are pleased with the progress of our collaboration and have enjoyed working with the Ripple team as we work together to bring these much-needed sustained release products to patients with critical unmet needs.” “This is the first of what we believe will be a number of transactions using our technology platform in concert with partners’ APIs to create sustained release implants which will benefit patients with extended duration and improved safety”, commented Tom Reeves, President & CEO, Ripple Therapeutics. “We look forward to continued collaboration with the entire Glaukos team.” About Ripple Therapeutics Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants. Ripple’s patented technology platform is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor both drug dose and duration. The advantages of this technology include lower molecular weight and higher drug loading allowing for smaller implants and a lack of degradation products which provides both a clearer regulatory path as well as an improved safety profile. With an extended duration of therapeutic benefit, this technology will also reduce the treatment burden for patients. www.rippletherapeutics.com Media Contact (Ripple) Julie Fotheringham, V.P. Marketing, People & Culture, Ripple Therapeutics M: 416-951-7988 E: jfotheringham@rippletherapeutics.com
September 23, 2024
Hemal Mehta, MBBS, MD (Cantab.), presented Efficacy and safety of the low dose dexamethasone IBE-814 IVT Implant for diabetic macular edema and retinal vein occlusion: Results of a first-in-human Phase 2 trial, at Euretina Congress in Barcelona, Spain, September 19-22, 2024. View Presentation
Share by: